Antifibrotic drug pirfenidone, a TGF-β1 inhibitor, has been identified from molecular information and transcriptomic data in a swine MI model (Aimo et al., 2022a), whereas evidence in humans has been limited to a phase 2 study evaluating extracellular volume changes with CMR (Aimo et al., 2022b). This evidence concerns the gene TGFB1 and myocardial infarction.